摘要
目的:观察α1肾上腺素能受体阻滞剂哈乐与抗胆碱药托特罗定联合应用对良性前列腺增生(BPH)伴下尿路症状(LUTS)患者的临床疗效。方法:对80例BPH伴LUTS病人采用随机、对照研究,分为治疗组和对照组,治疗组口服哈乐(200mg/qd)+托特罗定(1mg/bid),对照组口服哈乐(200mg/qd)。观察患者服药前、服药3周后,国际前列腺症状评分(IPSS)以及尿流动力学指标,如最大尿流率(UMAX),膀胱残余尿量和患者症状改善率。结果:治疗3周后,联合用药组UMAX、膀胱残余尿量和患者症状改善率均优于单独用药组,差异有统计学意义(P<0.01)。结论:哈乐与托特罗定联合应用较单纯使用哈乐可显著改善BPH伴LUTS患者的症状,其疗效可靠,安全可行。
Objective：To evaluate the clinical efficacy of alpha-1 adrenoceptor antagonist （Tamsulosin） and Tolterodine in the treatment of benign prostatic hyperplasia （BPH） patients with LUTS. Methods：Eighty BPH patients with LUTS were randomly divided into treatment group and control group of 40 patients each.The patients in treatment group use Tamsulosin（200mg/qd）＋ Tolterodine（1mg/bid,and patients in control group only use tamsulosin（200mg/qd）. Results：There was significantly difference between two groups （P 0. 01） after three weeks later. Conclusion：Treatment with Tamsulosin and Tolterodine was effective in raising the LUTS with BPH patients.
出处
《农垦医学》
2010年第2期129-131,共3页
Journal of Nongken Medicine
关键词
良性前列腺增生
哈乐
托特罗定
Benign prostatic hyperplasia
Tamsulosin
Tolterodine
